12 November 2014
EMA/PDCO/609719/2014
Procedure Management and Business Support Division

Paediatric Committee (PDCO)

Minutes of the 08-10 October 2014 meeting

Chair: Dirk Mentzer - Vice-chair: Koenraad Norga

Disclaimers

Some of the information contained in the PDCO minutes is considered commercially confidential or sensitive and therefore not disclosed in the present minutes. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the PDCO are on-going and therefore certain aspects of them are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Documents mentioned in these minutes cannot be released at present as they are currently in draft format or are classified as confidential. They will become public when adopted in their final form or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

I Introduction

I.1 Adoption of the minutes from previous meeting

The Minutes of the PDCO plenary session held on 10-12 September 2014 were adopted.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.2 Adoption of the Agenda

The agenda was adopted with amendments.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.3 Declaration of Conflict of Interest

See Annex I

I.4 External attendance

Please refer to the October 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the October 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the October 2014 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed total n. 93 procedures in total[1], of which:

- 29 paediatric investigation plan applications;
- 14 product-specific waiver applications;
- 18 compliance check procedures (interim and final);
- 32 requests for modifications of an agreed paediatric investigation plan.

IV Nomination

IV.1 Nomination of Rapporteurs and Peer reviewers

• List of letters of intent received for submission of applications with start of procedure December 2014[1] for Nomination of Rapporteur and Peer reviewer • Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	The PDCO approved the lists of Rapporteurs and Peer Reviewers.

IV.2 Nomination for other activities

V Update and finalisation of opinions and requests for modification

The opinions adopted during the Paediatric Committee meeting of October 2014 are published in the same month's meeting report published in the EMA website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

VI Discussion on the applicability of class waiver

Active substance	Proposed indication	Condition	Outcome	Potential paediatric interest of this medicine suggested by PDCO
4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide	Treatment of prostate cancer in adults	Treatment of prostate carcinoma (excluding rhabdomyosarcoma)	Confirmed	Not applicable

[1] The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

ABT-981	Treatment of osteoarthritis (OA) providing disease-modifying effects (including both structure and symptom modification)	Treatment of primary and secondary osteoarthrosis	Confirmed	Autoimmune and/or inflammatory disorders such as juvenile idiopathic arthritis
Ipatasertib (GDC-0068)	• Treatment of metastatic breast cancer; • Treatment of early stage breast cancer; • Treatment of castration-resistant prostate cancer (CRPC); • Treatment of inoperable locally-advanced or metastatic gastric including gastroesophageal junction adenocarcinoma	• Treatment of breast carcinoma; • Treatment of prostate carcinoma (excluding rhabdomyosarcoma); • Treatment of gastric adenocarcinoma	Confirmed	Paediatric malignancies driven by PI3K/Akt pathway activation

VII Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

No requests were received for the month of October 2014.

VIII Annual reports on deferrals

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
EMEA-000366-PIP02-09	Adalimumab	Humira	No	Yes	The PDCO noted the recruitment issues. A modification will be submitted in due time.
EMEA-000366-PIP04-12	Adalimumab	Humira	No	No	The report was noted.
EMEA-000597-PIP02-10	mirabegron	Betmiga	No	Yes	The report was noted. A modification request has been received.

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
EMEA-000969-PIP01-10	Cobicistat	Tybost	No	No	The PDCO noted the report. A modification will be submitted to refine cobicistat dosing.
EMEA-000060-PIP01-07	Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class (ACZ...	Ilaris	Yes	No	The report was noted.
EMEA-000060-PIP02-08	Canakinumab	Ilaris	Yes	No	The report was noted.
EMEA-000830-PIP02-10	Human normal immunoglobulin	Gammaplex	No	No	The report was noted.
EMEA-000196-PIP01-08	Telaprevir	Incivo	No	Yes	The study is not progressing according to plan due to recruitment difficulties. No modification is planned. A previous modification requesting a waiver received a negative PDCO opinion in July 2014.
EMEA-001071-PIP02-12	Certolizumab Pegol	Cimzia	No	No	The report was noted.
EMEA-000200-PIP01-08	Saxagliptin	Onglyza	No	Yes	The study is not progressing according to plan due to recruitment difficulties. The applicant is currently working with the EMA and FDA to develop an acceptable revised global saxagliptin

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
					paediatric development plan.
EMEA-000265-PIP01-08	golimumab	Simponi	No	No	The report was noted.
EMEA-000265-PIP02-11	golimumab	Simponi	No	No	The report was noted.
EMEA-000671-PIP01-09	Sildenafil citrate	Revatio	Yes	Yes	The report was noted.

IX Other topics

Guidelines	
Revision of the asthma guideline Marek Migdal	All comments received during public consultation phase will need to be commented upon, discussed and adopted by the committee at the next plenary meeting.
Workshop on the "Guideline on pharmaceutical development of medicines for paediatric use"	The Committee was informed about this workshop and was asked to nominate a member as workshop speaker.
Working groups	
White Paper Drafting Group	The group met in the margins of the Plenary meeting.
Paediatric oncology	The group discussed recent public meetings, subsequent activities and recent publications in paediatric oncology.
Neonatology	Discussion of general issues and ongoing activities in the neonatal field.
Election of the FWG Chair	Members were invited to submit their candidature as FWG Chair in advance of the election taking place at the November 2014 PDCO meeting.
Formulation	No non-product related issues were reported to the Committee.
Non-Clinical	No non-product related issues were reported to the Committee.
D30 Products identified for the Non-Clinical Working Group Jacqueline Carleer	Documents tabled for information.

Product-related topics	
Art.31 referral to PRAC investigating the potential risk of immediate and delayed hypersensitivity reactions with ambroxol and bromhexine-containing products: PDCO responses to PRAC list of questions Marek Migdal	The PDCO re-discussed and adopted the responses to the PRAC list of questions on the use of ambroxol and bromhexine containing products in the paediatric population.
Signal of cardiovascular events with the sodium containing medicines Angeliki Siapkara	The PDCO was informed on the signal of cardiovascular events with sodium containing medicines. The PRAC list of questions will be sent to the members along with the post-mail. The responses to the PRAC questions will be discussed at the next PDCO plenary meeting.
CMDh request for PDCO advice on contraindication of medicines used for the treatment of cough and cold in children below 6 years of age Angeliki Siapkara	The PDCO discussed and adopted the response to the CMDh on the request for contraindication of medicines used for the treatment of cough and cold in children below 6 years of age.
CHMP update on paediatric topics	The PDCO members were informed about the CHMP opinions on 2 medicinal products with paediatric indication and corresponding PIPs adopted in September 2014.
Other topics	
Development of PDCO Work Plan	The Committee was informed on progress of the PDCO work plan drafting group.
Workshop on dose finding at the EMA Ine Skottheim Rusten	The Committee was informed of the workshop.
The juvenile oncology project Jacqueline Carleer	Postponed to next meeting.
Flow of procedures and timely finalisation of Opinions	It was pointed out to PDCO members that changes to the draft Opinion should not be added in the later stages of the procedure, namely at D120, from either the applicant or the PDCO. Among other difficulties, such late changes prevent a proper scientific, regulatory and legal quality control of the draft Opinion. If the Applicant has not satisfactorily addressed the Requests for Modification adopted by the PDCO at D60, and substantial issues prevent the adoption of a positive Opinion, a negative Opinion should be adopted.

Update on Enpr-EMA activities	The committee was updated on 1. the recent EFGCP/DIA/EMA meeting on paediatric medicines, which saw Enpr-EMA's role in general and in particular for precompetitive collaboration between pharma companies 2. the revised EC guideline on the format and content of applications of Paediatric Investigation Plans that now explicitly encourages applicants to consult the paediatric research community, for example via Enpr-EMA, as early involvement may facilitate the development of a PIP.
Training on use of PedRA and Oracle BI	A training session on the use of the Paediatric Database (PedRA) and the reporting functions of Oracle Business Intelligence for PedRA was provided to the PDCO members who attended this optional session.
10-year Report to the European Commission	A representative from the European Commission illustrated plans on how to determine the financial impact of the paediatric regulation (for the EC 10 –year report).
New guideline on format and content	A representative from the European Commission presented new guideline on applications for paediatric investigation plans (PIP), now published on the EC website.

Any other business

None.

The Chair thanked all participants and closed the meeting.

Annex to the Minutes of the PDCO of October 2014

List of Participants and Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

No new or additional conflicts were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

PDCO Chair	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
Dirk Mentzer	Germany	Full Involvement	

PDCO Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
Karl-Heinz Huemer	Austria	Full Involvement	
Koenraad Norga	Belgium	Full Involvement	
Violeta Iotova	Bulgaria	No participation in discussions, final deliberations and voting	EMEA-C1-001097-PIP01-10-M02 EMEA-000694-PIP01-09-M04 EMEA-001677-PIP01-14 EMEA-001517-PIP02-14 EMEA-000128-PIP01-07-M06 EMEA-C-000412-PIP01-08-M01
Marina Dimov Di Giusti	Croatia	Full Involvement	
Marianne Orholm	Denmark	Full Involvement	
Irja Lutsar	Estonia	Full Involvement	
Pirjo Laitinen-Parkkonen	Finland	Full Involvement	
Sylvie Benchetrit	France	Full Involvement	
Grigorios Melas	Greece	Full Involvement	
Agnes Gyurasics	Hungary	Full Involvement	
Gylfi Oskarsson	Iceland	Full Involvement	

PDCO Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Dina Apele-Freimane	Latvia	Full Involvement	
Carola de Beaufort	Luxembourg	Full Involvement	
Hendrik van den Berg	Netherlands	Full Involvement	
Siri Wang	Norway	Full Involvement	
Marek Migdal	Poland	No participation in final deliberations and voting	EMEA-000181-PIP02-13 EMEA-001558-PIP02-14
Helena Fonseca	Portugal	Full Involvement	
Dana Gabriela Marin	Romania	Full Involvement	
Michaela Meciakova	Slovakia	Full Involvement	
Stefan Grosek	Slovenia	Full Involvement	
Fernando de Andrés Trelles	Spain	Full Involvement	
Viveca Lena Odlind	Sweden	Full Involvement	
Angeliki Siapkara	United Kingdom	Full Involvement	

PDCO Member Connected via TC	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Paolo Rossi	Italy	Connected via TC for EMEA-001631-PIP01-14 and EMEA-C1-000804-PIP01-09-M02	
Peter Szitanyi	Czech Republic	Connected via TC for EMEA-001530-PIP02-14	

PDCO Alternate	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Jacqueline Carleer	Belgium	Full Involvement	
Marina Fertek	Czech Republic	Replacing PDOC member	
		No participation in final deliberations and voting	EMEA-000694-PIP01-09-M04 EMEA-001677-PIP01-14 EMEA-000128-PIP01-07-M06 EMEA-C-000412-PIP01-08-M01
Marta Granström	Denmark	Full Involvement	
Immanuel Barth	Germany	Replacing PDOC member	
		Full involvement	
Brian Aylward	Ireland	Replacing PDCO member	
		Also connected via TC for EMEA-001231-PIP02-13-M01	
Herbert Lenicker	Malta	Replacing PDCO member	

PDCO Alternate	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Ine Skottheim Rusten	Norway	Full Involvement	
Jolanta Witkowska-Ożogowska	Poland	Full Involvement	
Hugo Tavares	Portugal	Full Involvement	
Maria Jesús Fernández Cortizo	Spain	Full Involvement	
Ninna Gullberg	Sweden	Full Involvement	
Martina Riegl	United Kingdom	Full Involvement	

PDCO Representative of doctors' organisations	Role	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Antje Neubert	Member	Representative of doctors' organisations	Full Involvement	
Paolo Paolucci	Alternate	Representative of doctors' organisations	Full Involvement	
Doina Plesca	Alternate	Representative of doctors' organisations	Replacing PDCO member	
			No participation in discussions, final deliberations and voting	EMEA-001613-PIP01-14 EMEA-000431-PIP01-08-M07 EMEA-000069-PIP04-13 EMEA-000467-PIP01-08-M06 EMEA-001504-PIP02-13 EMEA-000127-PIP01-07-M03
Riccardo Riccardi	Member	Representative of doctors' organisations	Full Involvement	

PDCO Representative of patients' organisations	Role	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Paola Baiardi	Alternate	Representative of patients' organisations	Replacing PDCO member	
			Full Involvement	
Kerry Leeson-Beevers	Alternate	Representative of patients' organisations	Replacing PDCO member	
			Full Involvement	

PDCO Representative of patients' organisations by phone	Role	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Michal Odermarsky	Member	Representative of patients' organisations	No participation in discussions, final deliberations and voting	EMEA-001661-PIP01-14 EMEA-C1-000804-PIP01-09-M02
			Connected via TC for EMEA-001636-PIP01-14	

European Commission	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Representative	European Commission	Full involvement	

PDCO Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
*Experts were only evaluated against the product they have been invited to talk about.			
Sabine Scherer	Germany	Full Involvement	
Nasir Hussain	United Kingdom	Full Involvement	
Juliana Min	United Kingdom	No participation in discussions, final deliberations and voting EMEA-001645-PIP01-14 EMEA-001690-PIP01-14 EMEA-001689-PIP01-14 EMEA-001585-PIP01-13 EMEA-001672-PIP01-14 EMEA-001559-PIP01-13 EMEA-001429-PIP01-13 EMEA-001651-PIP01-14 EMEA-000341-PIP02-09-M01 EMEA-000780-PIP01-09-M01 EMEA-000120-PIP01-07-M05 EMEA-000454-PIP01-08-M05 EMEA-001631-PIP01-14 EMEA-C1-000804-PIP01-09-M02 EMEA-001656-PIP01-14 EMEA-001654-PIP01-14 EMEA-001620-PIP01-14 EMEA-001612-PIP01-14 EMEA-001147-PIP01-11-M02	
Dominik Karres	United Kingdom	Involvement in discussions only EMEA-001585-PIP01-13 EMEA-001147-PIP01-11-M02	

PDCO Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
Johannes Hendrikus Ovelgönne	Netherlands	Full Involvement	

PDCO Expert By phone	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
*Experts were only evaluated against the product they have been invited to talk about.			
Amany Al-Gazayerly	Netherlands	Full Involvement	
Joerg Zinserling	Germany	Full Involvement	
Adrienn Horvath	Hungary	Full Involvement	
Outi Mäki-Ikola	Finland	Full Involvement	
Eeva Sofia Leinonen	Finland	Full Involvement	